Literature DB >> 26589229

Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.

Hrishikesh Samant1, Devendra Desai2, Philip Abraham2, Anand Joshi2, Tarun Gupta2, Alpa Dherai3, Tester Ashavaid3.   

Abstract

INTRODUCTION: In clinical practice, endoscopic findings are often used for assessing disease activity in inflammatory bowel disease (IBD). In recent years, blood and stool markers are being increasingly used for this purpose. Among them, the fecal calprotectin (FC) level is probably the most favored. Data on the reliability of FC are lacking from countries like India, where gut infections are common.
OBJECTIVE: The aims of this study were to compare the FC level with the erythrocyte sedimentation rate (ESR) and the C-reactive protein (CRP) as non-invasive markers of IBD and, in patients with ulcerative colitis (UC), and to study its correlation with disease extent, clinical activity, and endoscopic severity.
METHODS: Records of patients with IBD who had tests for FC, ESR and CRP and colonoscopy done within a 2-week period, between 2012 and 2014, were retrieved. Sixty-three patients (UC 32, Crohn's disease [CD] 31) were included for analysis. ESR, CRP and FC were compared to endoscopy to assess inflammation.
RESULTS: Patients with UC had higher levels of FC than those with ileocolonic CD (median FC 800 mcg/g vs. 619 mcg/g, respectively; p = 0.04). FC levels correlated with CRP (r = 0.4, p < 0.001) but not with ESR (r = 0.21, p = 0.09). In patients with UC with endoscopic evidence of inflammation, more (86.9 %) had FC > 200 mcg/g (cut-off for disease activity in our laboratory) than had ESR >20 mm in the first hour (60.6 %) or positive CRP (65.6 %) (< 0.01); FC levels increased with increasing endoscopic Mayo score (p = 0.001) and Truelove-Witt's clinical severity score (p = 0.006), but did not correlate with disease extent (p = 0.7). The best FC cut-off level to identify 'active UC' (Mayo grade 2 or more) was 800 mcg/g.
CONCLUSION: Fecal calprotectin level correlates with CRP but not with ESR. In patients with UC with inflammation, FC > 200 mcg/g is more often positive than raised ESR or CRP; it also correlates with clinical and endoscopic activity but not with disease extent. FC level > 800 mcg/g can be used to differentiate active from inactive UC.

Entities:  

Keywords:  C-reactive protein; Fecal calprotectin; Inflammatory markers

Mesh:

Substances:

Year:  2015        PMID: 26589229     DOI: 10.1007/s12664-015-0608-x

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  31 in total

Review 1.  Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity.

Authors:  Satoru Yui; Yuichi Nakatani; Masaaki Mikami
Journal:  Biol Pharm Bull       Date:  2003-06       Impact factor: 2.233

2.  Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.

Authors:  Jost Langhorst; Sigrid Elsenbruch; Julia Koelzer; Andreas Rueffer; Andreas Michalsen; Gustav J Dobos
Journal:  Am J Gastroenterol       Date:  2007-10-04       Impact factor: 10.864

Review 3.  Clinical perspectives in Crohn's disease. Objective measures of disease activity: alternatives to symptom indices.

Authors:  Edward V Loftus
Journal:  Rev Gastroenterol Disord       Date:  2007

4.  A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis.

Authors:  Triana Lobatón; Francisco Rodríguez-Moranta; Alicia Lopez; Elena Sánchez; Lorena Rodríguez-Alonso; Jordi Guardiola
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

5.  Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease.

Authors:  Roberto Berni Canani; Laura Tanturri de Horatio; Gianluca Terrin; Maria Teresa Romano; Erasmo Miele; Annamaria Staiano; Luciano Rapacciuolo; Gaetano Polito; Vincenzo Bisesti; Francesco Manguso; Gianfranco Vallone; Antonio Sodano; Riccardo Troncone
Journal:  J Pediatr Gastroenterol Nutr       Date:  2006-01       Impact factor: 2.839

6.  Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.

Authors:  Erik Mooiweer; Mirjam Severs; Marguerite E I Schipper; Herma H Fidder; Peter D Siersema; Robert J F Laheij; Bas Oldenburg
Journal:  J Crohns Colitis       Date:  2014-11-26       Impact factor: 9.071

7.  Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.

Authors:  Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Ekaterina Safroneeva; Yvonne Romero; David Armstrong; Carsten Schmidt; Michael Trummler; Valérie Pittet; Stephan R Vavricka
Journal:  Inflamm Bowel Dis       Date:  2013-02       Impact factor: 5.325

Review 8.  Medical management of severe ulcerative colitis.

Authors:  Justin C Chang; Russell D Cohen
Journal:  Gastroenterol Clin North Am       Date:  2004-06       Impact factor: 3.806

9.  Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis.

Authors:  Jun-Ying Xiang; Qin Ouyang; Guo-Dong Li; Nan-Ping Xiao
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

10.  Fecal calprotectin and clinical disease activity in pediatric ulcerative colitis.

Authors:  Kaija-Leena Kolho; Dan Turner
Journal:  ISRN Gastroenterol       Date:  2013-02-26
View more
  4 in total

1.  Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis.

Authors:  Sun-Ho Lee; Min-Ju Kim; Kiju Chang; Eun Mi Song; Sung Wook Hwang; Sang Hyoung Park; Dong-Hoon Yang; Kyung-Jo Kim; Jeong-Sik Byeon; Seung-Jae Myung; Suk-Kyun Yang; Byong Duk Ye
Journal:  BMC Gastroenterol       Date:  2017-10-23       Impact factor: 3.067

2.  Does faecal calprotectin differentiate between inflammatory bowel disease colitis and non-inflammatory bowel disease colitides?

Authors:  Ahmed F Khalil; Ekram M Helmy; Mohamed N Massoud; Nahed M Baddour; Rasha H Metwally; Omneya M Omar
Journal:  Prz Gastroenterol       Date:  2020-11-27

Review 3.  Inflammatory bowel disease in India - Past, present and future.

Authors:  Gautam Ray
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742

4.  Optimal cut-off value of fecal calprotectin for the evaluation of ulcerative colitis: An unsolved issue?

Authors:  Ashish Kumar Jha; Madhur Chaudhary; Vishwa Mohan Dayal; Amarendra Kumar; Sanjeev Kumar Jha; Praveen Jha; Shubham Purkayastha; Ravish Ranjan
Journal:  JGH Open       Date:  2018-08-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.